<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68767">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845740</url>
  </required_header>
  <id_info>
    <org_study_id>IMMU-115-04</org_study_id>
    <nct_id>NCT01845740</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of SC Milatuzumab in SLE</brief_title>
  <official_title>A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunomedics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunomedics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Milatuzumab will be given subcutaneously at different dose levels once or twice weekly
      (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus
      (SLE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Milatuzumab will be given subcutaneously at different dose levels once or twice weekly
      (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus
      (SLE).  The treatment portion of the study lasts 4 weeks.  Then patients are followed for
      disease activity for at least 12 weeks. If patients respond to the study drug, they may be
      eligible for one course of retreatment, again followed by 12 weeks of follow-up.  Patients
      who showed a response will continue to be followed at timepoints up to one year after
      treatment to assess how long the response lasts.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>safety</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety of the subcutaneously administered milatuzumab will be assessed using laboratory and clinical data comparing baseline lab results and clinical condition to the lab results and clinical condition/adverse events during treatment and follow-up timepoints up to 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed using the BILAG scoring model for lupus disease activity and symptoms by comparing baseline BILAG measurements against the BILAG measurements obtained during treatment and during follow-up for up to 2 years.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lupus Erythematosus, Cutaneous</condition>
  <condition>Lupus Erythematosus, Discoid</condition>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Lupus Vasculitis, Central Nervous System</condition>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Milatuzumab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Milatuzumab is the study drug that will be administered subcutaneously at 3 different dose levels once or twice weekly for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>milatuzumab</intervention_name>
    <description>Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form.  In this study, milatuzumab is being given subcutaneously in patients with lupus.</description>
    <arm_group_label>Milatuzumab SC</arm_group_label>
    <other_name>Milatuzumab is a Cd74 targeted humanized monoclonal antibody.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years old

          -  Signed written informed consent before study entry

          -  Diagnosis of SLE by American College of Rheumatology revised criteria (meets ≥ 4
             criteria)

          -  Positive ANA (titer ≥ 1:80) at study entry

          -  At least 2 BILAG B scores (but no A's) in any organ/body system

          -  Receiving at least 5.0 mg/day oral prednisone (or equivalent) at stable doses for at
             least 4 weeks prior to study entry

          -  If receiving immunosuppressives or antimalarial agents, at stable doses for at least
             4 weeks prior to study entry

        Exclusion Criteria:

          -  Pregnant or lactating women.  Women of childbearing potential must have a negative
             pregnancy test.

          -  Women of childbearing potential and fertile men not practicing or unwilling to
             practice birth control during the study

          -  Rituximab, belimumab, other prior antibody, investigational or experimental therapy
             within 6 months

          -  Allergic to murine, chimeric, humanized or human antibodies

          -  Hematologic abnormalities not attributed to lupus: hemoglobin &lt; 8.0 mg/dL, WBC &lt;
             2000/L, ANC &lt; 1500/L, platelets &lt; 50,000/L,

          -  AST, ALT or alkaline phosphatase &gt; 3 times upper limit of normal and not attributed
             to lupus

          -  Serum creatinine &gt; 2.5 mg/dL, proteinuria &gt; 3.5 g/day

          -  Received live vaccine within 4 weeks

          -  Thrombosis, spontaneous or induced abortion, stillbirth or live birth within 4 weeks

          -  Antiphospholipid antibodies AND a history of thromboembolic events

          -  On oral anticoagulants (not including NSAIDs) within 4 weeks

          -  Active infection with antibiotics within 7 days

          -  Infection requiring hospitalization or herpes zoster treatment within 4 weeks

          -  Long-term infectious diseases (tuberculosis, fungal infections) active within 2 years

          -  Malignancy (except squamous or basal cell carcinoma, cervical CIS) within 3 years
             (unless approved by the medical monitor)

          -  History of recurrent abortions (2 or more)

          -  Known HIV, hepatitis B or C, other immunosuppressive states

          -  Other concurrent medical conditions that, in the investigator's opinion, could affect
             the patient's ability to tolerate or complete the study will not be eligible for the
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunomedics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Horne</last_name>
    <phone>973-605-8200</phone>
    <phone_ext>173</phone_ext>
    <email>hhorne@immunomedics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fran Bozza</last_name>
    <phone>973-605-8200</phone>
    <phone_ext>175</phone_ext>
    <email>fbozza@immunomedics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center-Wallace Rheumatic Study Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Frölich D, Blassfeld D, Reiter K, Giesecke C, Daridon C, Mei HE, Burmester GR, Goldenberg DM, Salama A, Dörner T. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther. 2012 Mar 9;14(2):R54. doi: 10.1186/ar3767.</citation>
    <PMID>22404985</PMID>
  </reference>
  <reference>
    <citation>Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988. Epub 2012 Jan 23.</citation>
    <PMID>22271448</PMID>
  </reference>
  <reference>
    <citation>Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RA. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 2011 Dec 22;118(26):6893-903. doi: 10.1182/blood-2011-06-363879. Epub 2011 Oct 31. PubMed PMID: 22042694; PubMed Central PMCID: PMC3568700.</citation>
    <PMID>22042694</PMID>
  </reference>
  <reference>
    <citation>Santana JM, Grellier P, Rodier MH, Schrevel J, Teixeira A. Purification and characterization of a new 120 kDa alkaline proteinase of Trypanosoma cruzi. Biochem Biophys Res Commun. 1992 Sep 30;187(3):1466-73.</citation>
    <PMID>1417823</PMID>
  </reference>
  <reference>
    <citation>Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.</citation>
    <PMID>21228331</PMID>
  </reference>
  <reference>
    <citation>Hertlein E, Triantafillou G, Sass EJ, Hessler JD, Zhang X, Jarjoura D, Lucas DM, Muthusamy N, Goldenberg DM, Lee RJ, Byrd JC. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood. 2010 Oct 7;116(14):2554-8. doi: 10.1182/blood-2009-11-253203. Epub 2010 Jun 23.</citation>
    <PMID>20574049</PMID>
  </reference>
  <reference>
    <citation>Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs. 2010 Jan;19(1):141-9. doi: 10.1517/13543780903463854. Review.</citation>
    <PMID>19968579</PMID>
  </reference>
  <reference>
    <citation>Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res. 2009 Apr 15;15(8):2808-17. Epub 2009 Apr 7.</citation>
    <PMID>19351768</PMID>
  </reference>
  <reference>
    <citation>Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009 Jan;18(1):99-104. Review.</citation>
    <PMID>19053886</PMID>
  </reference>
  <reference>
    <citation>Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s. Review.</citation>
    <PMID>17875789</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic lupus erythematoses</keyword>
  <keyword>lupus</keyword>
  <keyword>SLE</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
    <mesh_term>Lupus Erythematosus, Discoid</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Vasculitis, Central Nervous System</mesh_term>
    <mesh_term>Lupus Vasculitis, Central Nervous System</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
